Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Atezolizumab-obinutuzumab-venetoclax in follicular lymphoma and MZL

Charles Herbaux, MD, MSc, University Hospital of Lille, Lille, France, gives an overview of the findings of the primary analysis of a Phase II trial of atezolizumab plus venetoclax and obinutuzumab for the treatment of patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma (MZL). 58 patients with follicular lymphoma were enrolled in the trial with a median follow-up of 14.5 months, and 20 patients with MZL were enrolled in the trial with a median follow-up of 11.9 months. The follicular lymphoma cohort reported an overall response rate (ORR) of 53.6% and the MZL cohort reported an ORR of 66.76%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Transcript (edited for clarity)

I’m happy to share those first results of our Phase II trial evaluating three drugs: atezolizumab, an anti-PD-L1 antibody, obinutuzumab, an anti-CD20 antibody, and venetoclax, a small-molecule inhibiting BCL2. So, those three drugs were given to relapsed and refractory follicular lymphoma and marginal zone lymphomas.

And we are sharing during EHA the first results with no safety signal brought by the combination of the three drugs...

I’m happy to share those first results of our Phase II trial evaluating three drugs: atezolizumab, an anti-PD-L1 antibody, obinutuzumab, an anti-CD20 antibody, and venetoclax, a small-molecule inhibiting BCL2. So, those three drugs were given to relapsed and refractory follicular lymphoma and marginal zone lymphomas.

And we are sharing during EHA the first results with no safety signal brought by the combination of the three drugs. So, that’s really a good news. And we have the toxicity of the single drugs with some cytopenias, and some autoimmune adverse events brought by atezolizumab probably, but everything was manageable, and, for example, we had only one neutropenia on our cohorts.

So, we had 58 follicular lymphoma with an overall response rate of 53%, and we have also 20 marginal zone lymphomas with an overall response rate of 66.7%. So, this is some primary results, but this is really promising without chemo and with the responses that are durable so far with a median follow-up of 14 months.

Read more...